Last reviewed 2026-04-19 · How we verify

PF-05221304 administered Day 7-14

Pfizer · Phase 1 active Small molecule

PF-05221304 administered Day 7-14 is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.

At a glance

Generic name	PF-05221304 administered Day 7-14
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-05221304 administered Day 7-14 CI brief — competitive landscape report
PF-05221304 administered Day 7-14 updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about PF-05221304 administered Day 7-14

What is PF-05221304 administered Day 7-14?

PF-05221304 administered Day 7-14 is a Small molecule drug developed by Pfizer.

Who makes PF-05221304 administered Day 7-14?

PF-05221304 administered Day 7-14 is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is PF-05221304 administered Day 7-14 in?

PF-05221304 administered Day 7-14 is in Phase 1.

Manufacturer: Pfizer — full pipeline
Compare: PF-05221304 administered Day 7-14 vs similar drugs
Pricing: PF-05221304 administered Day 7-14 cost, discount & access